TGFB1 and cancer: Based on results in the field of cancer immunotherapy and our own experimental results, we propose that interventions, including HDACi, that reverse immune dysfunction, stimulating i) antigen specific immune responses28, ii) the production of IFNs pre-ATI, and iii) inhibit the production and downstream functions of TGF-β, can intercept viral rebound and promote viral reservoir decay post-ATI.